Search CPMD
CANNAPHARMARX, INC.
OTC · CIK 1081938
Last close0
Daily change-0.00 (-0.00%)
10 Years gain-99.71%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CPMD · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
57.4Momentum
100.0Acceleration
100.0Confidence
71.0Annual Revenue13
Quarterly Revenue41
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency19.9 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 175.7885 percentage points.
Operating leverageOperating margin improved by 153.0943 percentage points.
Warnings
Low interest coverage · HIGHInterest coverage is -1.4271x.
Key Metrics
Revenue Growth TTM58.63%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin-89.8%OK
Operating Margin-158.37%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-3.26%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.02%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.36M | -$2.08M | -$3.35M | -$789,102.00 | -$794,621.00 | -153.06% | -245.77% | -58.34% | n/a | 662.5M |
| 2025 FY Dec 31, 2024 | $820,137.00 | -$2.93M | -$3.63M | -$1.70M | -$1.70M | -357.86% | -442.72% | -206.94% | n/a | 625.28M |
| 2024 FY Dec 31, 2023 | $0.00 | $0.00 | -$1.58M | -$2.27M | -$2.36M | n/a | n/a | n/a | -48.15% | 308.94M |
| 2022 FY Dec 31, 2022 | $0.00 | $0.00 | -$5.21M | -$1.45M | n/a | n/a | n/a | n/a | -187.64% | 211.04M |
| 2022 FY Dec 31, 2021 | $0.00 | $0.00 | -$2.99M | -$2.41M | n/a | n/a | n/a | n/a | n/a | 74.69M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.79M | sum latest 4 fiscal quarters Revenue | OK | 0001683168-26-006570, 0001654954-25-013083 |
| Revenue Growth TTM | 58.63% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001683168-26-006570, 0001654954-25-013083 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001654954-26-003108 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001654954-26-003108 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001654954-26-003108 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001683168-26-006570, 0001654954-25-013083 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | -89.8% | Gross Profit / Revenue | OK | 0001683168-26-006570, 0001654954-25-013083 |
| Operating Margin | -158.37% | Operating Income / Revenue | OK | 0001683168-26-006570, 0001654954-25-013083 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001683168-26-006570 |
| Interest Coverage | -1.43x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 0.04x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001683168-26-006570, 0001654954-25-013083 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |